scholarly journals PPAR-γ Gene Expression in Human Adipose Tissue Is Associated with Weight Loss After Sleeve Gastrectomy

2021 ◽  
Author(s):  
Jorge-Luis Torres ◽  
Ricardo Usategui-Martín ◽  
Lourdes Hernández-Cosido ◽  
Edgar Bernardo ◽  
Laura Manzanedo-Bueno ◽  
...  
Keyword(s):  
Weight Loss ◽  
Adipose Tissue ◽  
Sleeve Gastrectomy ◽  
Morbidly Obese ◽  
Peroxisome Proliferator ◽  
Obese Patients ◽  
Peroxisome Proliferator Activated Receptor ◽  
Clinical Variables ◽  
Ppar Γ ◽  
Obese Subjects

Abstract Background The peroxisome proliferator-activated receptor (PPAR)-γ plays a key role in adipose tissue differentiation and fat metabolism. However, it is unclear which factors may regulate its expression and whether obese patients have changes in adipose tissue expression of PPAR-γor potential regulators such as miR-27. Thus, our aims were to analyze PPAR-γ and miR-27 expression in adipose tissue of obese patients, and to correlate their levels with clinical variables. Subjects and Methods. We included 43 morbidly obese subjects who underwent sleeve gastrectomy (31 of them completed 1-year follow-up) and 19 non-obese subjects. mRNA expression of PPAR-γ1 and PPAR-γ2, miR-27a, and miR-27b was measured by qPCR in visceral and subcutaneous adipose tissue. Clinical variables and serum adipokine and hormone levels were correlated with PPAR-γ and miR-27 expression. In addition, a systematic review of the literature regarding PPAR-γ expression in adipose tissue of obese patients was performed. Results We found no differences in the expression of PPAR-γ and miR-27 in adipose tissue of obese patients vs. controls. The literature review revealed discrepant results regarding PPAR-γ expression in adipose tissue of obese patients. Of note, we described a significant negative correlation between pre-operative PPAR-γ1 expression in adipose tissue of obese patients and post-operative weight loss, potentially linked with insulin resistance markers. Conclusion PPAR-γ1 expression in adipose tissue is associated with weight loss after sleeve gastrectomy and may be used as a biomarker for response to surgery.

scholarly journals Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss

2006 ◽  
Vol 155 (1) ◽  
pp. 161-165 ◽  
Author(s):  
M J Kim ◽  
M Maachi ◽  
C Debard ◽  
E Loizon ◽  
K Clément ◽  
...  
Keyword(s):  
Weight Loss ◽  
Adipose Tissue ◽  
Insulin Sensitivity ◽  
Metabolic Parameters ◽  
Peroxisome Proliferator ◽  
Mrna Levels ◽  
Very Low Calorie Diet ◽  
Peroxisome Proliferator Activated Receptor ◽  
Before And After ◽  
Obese Subjects

Objective: To investigate the mRNA expression of adiponectin, AdipoR1 and AdipoR2, the two recently cloned adiponectin receptors and peroxisome proliferator activated receptor (PPAR)γ2 in adipose tissue of obese individuals before and during a very low calorie diet (VLCD) inducing weight loss. Methods: Twenty-three non-diabetic obese subjects with normal (NGT, n=11) or impaired glucose tolerance (IGT, n=12) (age, 47±3 years; body mass index, 39.3±1.3 kg/m2) were studied before and after a 3-week 3.9 MJ diet daily without exercise. mRNA levels of nine IGT and six NGT subjects were measured by real-time PCR in s.c. abdominal adipose tissue. Results: Metabolic parameters and insulin sensitivity were improved by VLCD in the IGT group, but minimally affected in the NGT group. VLCD increased expression of AdipoR1 in the IGT (P=0.02), but not in the NGT group. Adiponectin, AdipoR2 and PPARγ2 mRNA levels did not change during VLCD in any group. In the IGT, but not in the NGT group, AdipoR1 and AdipoR2 expressions were positively related to that of PPARγ2 and, after VLCD, AdipoR1 and AdipoR2 expressions were positively related to each other and to that of adiponectin. Conclusion: In the NGT group, the 3-week VLCD inducing weight loss did not modify metabolic parameters, insulin sensitivity and the expression of the adiponectin system in adipose tissue. By contrast, in the IGT group, AdipoR1 expression increased and we found a coordinate regulation of the expression of adiponectin and its receptors. These modifications could participate, through adiponectin action on adipocytes, to the improved metabolic parameters observed in IGT subjects.

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AND GROWTH HORMONE SEGRETAGOGUE RECEPTOR-1A MRNA EXPRESSION IN ADIPOSE TISSUE OBTAINED FROM SEVERELY OBESE PATIENTS

2018 ◽  
Vol 25 (3) ◽  
pp. 219
Author(s):  
Bianca Codrina Morarasu ◽  
Raluca Ecaterina Haliga ◽  
Daniel Timofte ◽  
Ioana Hristov ◽  
Iustina Silivestru-Cretu ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Adipose Tissue ◽  
Mrna Expression ◽  
Peroxisome Proliferator ◽  
Obese Patients ◽  
Peroxisome Proliferator Activated Receptor ◽  
Severely Obese

Agouti regulates adipocyte transcription factors

2001 ◽  
Vol 280 (4) ◽  
pp. C954-C961 ◽  
Author(s):  
Randall L. Mynatt ◽  
Jacqueline M. Stephens
Keyword(s):  
Adipose Tissue ◽  
Transgenic Mice ◽  
Ectopic Expression ◽  
Peroxisome Proliferator ◽  
Paracrine Factor ◽  
Peroxisome Proliferator Activated Receptor ◽  
Protein Levels ◽  
Skeletal Mass ◽  
Ppar Γ ◽  
Obesity And Diabetes

Agouti is a secreted paracrine factor that regulates pigmentation in hair follicle melanocytes. Several dominant mutations cause ectopic expression of agouti, resulting in a phenotype characterized by yellow fur, adult-onset obesity and diabetes, increased linear growth and skeletal mass, and increased susceptibility to tumors. Humans also produce agouti protein, but the highest levels of agouti in humans are found in adipose tissue. To mimic the human agoutiexpression pattern in mice, transgenic mice (aP2-agouti) that express agouti in adipose tissue were generated. The transgenic mice develop a mild form of obesity, and they are sensitized to the action of insulin. We correlated the levels of specific regulators of insulin signaling and adipocyte differentiation with these phenotypic changes in adipose tissue. Signal transducers and activators of transcription (STAT)1, STAT3, and peroxisome proliferator-activated receptor (PPAR)-γ protein levels were elevated in the transgenic mice. Treatment of mature 3T3-L1 adipocytes recapitulated these effects. These data demonstrate that agouti has potent effects on adipose tissue. We hypothesize that agouti increases adiposity and promotes insulin sensitivity by acting directly on adipocytes via PPAR-γ.

scholarly journals Increase in Brown Adipose Tissue Activity after Weight Loss in Morbidly Obese Subjects

2012 ◽  
Vol 97 (7) ◽  
pp. E1229-E1233 ◽  
Author(s):  
G. H. E. J. Vijgen ◽  
N. D. Bouvy ◽  
G. J. J. Teule ◽  
B. Brans ◽  
J. Hoeks ◽  
...  
Keyword(s):  
Weight Loss ◽  
Adipose Tissue ◽  
Brown Adipose Tissue ◽  
Morbidly Obese ◽  
Brown Adipose ◽  
Obese Subjects ◽  
Brown Adipose Tissue Activity

Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Achieve Comparable Weight Loss at 1 Year

2012 ◽  
Vol 78 (12) ◽  
pp. 1325-1328 ◽  
Author(s):  
Arezou Yaghoubian ◽  
Amy Tolan ◽  
Bruce E. Stabile ◽  
Amy H. Kaji ◽  
Gary Belzberg ◽  
...  
Keyword(s):  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Excess Weight Loss ◽  
Weight Loss Program ◽  
Excess Weight ◽  
Morbidly Obese ◽  
Preoperative Weight Loss ◽  
Obese Patients ◽  
Laparoscopic Rygb ◽  
Preoperative Weight

Laparoscopic sleeve gastrectomy has gained popularity as a weight loss surgical option for morbidly obese patients. Although initial studies have shown weight loss and comorbidity resolution comparable to those after laparoscopic Roux-en-Y gastric bypass (RYGB), many of these studies are limited by the small patient size. Thus, the purpose of this study was to compare the outcomes of laparoscopic sleeve gastrectomy and laparoscopic RYGB. A retrospective chart review of all morbidly obese patients who underwent laparoscopic RYGB or sleeve gastrectomy between 2007 and 2009 at an HMO hospital was conducted. Data points collected included age, gender, completion of a preoperative weight loss program, initial body mass index (BMI), pre- and postoperative weights, and presence of diabetes mellitus (DM), hypertension (HTN), osteoarthritis, obstructive sleep apnea, and gastroesophageal reflux disease (GERD). Outcomes measures included excess weight loss, resolution of comorbidities, postoperative complications, and mortality. A total of 345 laparoscopic RYGBs and 192 sleeve gastrectomies were performed. On average, the patients who received RYGB were younger (46 vs 48 years, P = 0.05) and had higher BMI (47 vs 43 kg/m2, P < 0.0001). There was a higher incidence of DM in the RYGB group (32 vs 22%, P = 0.01), whereas the incidences of HTN and GERD were similar in both surgical groups. Ninety-three per cent of the patients who underwent RYGB and 90 per cent of the patients who underwent sleeve gastrectomy completed a preoperative weight loss program. The median length of hospital stay for both groups was 3 days. The complication rate in both groups was 9 per cent. The incidence of gastric leak was 1 per cent in both groups. There was only one mortality, which occurred in the RYGB group. The postoperative resolution of DM was comparable in both groups. The RYGB group had greater resolution of HTN (48 vs 34%, P = 0.03) and GERD (73 vs 34%, P < 0.0001). At 12 months, sleeve gastrectomy achieved superior excess weight loss compared with RYGB (72 vs 61%, P = 0.0015). After adjusting for age and BMI, the excess weight loss for RYGB and sleeve gastrectomy was similar at 12 months (t parameter estimate -0.06, P = 0.08). Laparoscopic RYGB and sleeve gastrectomy had comparable postoperative morbidity and mortality rates. At 1 year, sleeve gastrectomy achieved only slightly greater weight loss. The two operations are both legitimate standalone bariatric procedures and their applications need to be based on individual patient characteristics and needs.

Dysregulation of gene expression within the peroxisome proliferator activated receptor pathway in morbidly obese patients

2008 ◽  
Vol 23 (6) ◽  
pp. 1292-1297 ◽  
Author(s):  
A. Katharine Hindle ◽  
Jadd Koury ◽  
Tim McCaffrey ◽  
Sidney W. Fu ◽  
Fred Brody
Keyword(s):  
Gene Expression ◽  
Morbidly Obese ◽  
Peroxisome Proliferator ◽  
Obese Patients ◽  
Peroxisome Proliferator Activated Receptor
Sign in / Sign up

Export Citation Format

Share Document